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It is estimated that a highly penetrant genetic
predisposition is the cause of 10-20% of all colorectal
cancers (CRC)[1-5].
Among the well known syndromes of inherited
predisposition to tumours manifesting with CRC,
syndromes showing a Mendelian pattern of inheritance
include: hereditary nonpolyposis colorectal cancer
(HNPCC, Lynch syndrome), familial adenomatous
polyposis (FAP), Gardner, Turcot and Peutz-Jeghers
syndromes, and juvenile polyposis.
L Ly yn nc ch h   s sy yn nd dr ro om me e   ( (H HN NP PC CC C) )
HNPCC was described by Lynch [6] in the 1960s
and is the cause of around 5% of all CRC. It has been
shown that HNPCC is caused by mutations within
several genes such as: MSH2, MLH1, MSH6, PMS2.
Mutation within MSH2 and MLH1 are the most frequent
cause of Lynch syndrome [7-10]. Characteristic clinical
features of Lynch syndrome include:
• early age of CRC diagnosis (about 45 years),
• more frequent right side tumour localization,
• two or more CRC cases among first degree relatives,
• many syn- and meta-chronous CRC tumours,
• occurrence of disease in consecutive generations
(vertical transmission),
• increased frequency of occurrence among relatives
of cancers of the endometrium, small bowel and
urinary tract.
According to an international group of experts (the
International Collaborative Group on HNPCC – ICG-
HNPCC) Lynch syndrome can be definitively diagnosed
if constitutional mutations within one of the genes
connected with HNPCC, such as MSH2 or MLH1, is
identified or if the following pedigree-clinical criteria
are matched (Table 1).
A family matching the definitive criteria of HNPCC
according to the ICG-HNPCC are presented in Figure 1.
Due to incomplete penetrance of genes, which is
typical for dominant Mendelian disorders, deaths
caused by various diseases, or due to difficulties in
achieving full information about all relatives, a large
proportion – perhaps the majority – of families with
HNPCC cannot be diagnosed using the Amsterdam
criteria summarized in Table 1.
Therefore several authors use another type of criteria,
fulfilment of which does not allow definitive diagnosis of
HNPCC, but is useful in identifying of families with 
T Ta ab bl le e   1 1. .   Diagnostic criteria of HNPCC according to ICG-HNPCC [11]
1. At least 3 relatives are affected by histologically verified 
CRC or cancer of the endometrium, small bowel or urinary 
tract; at least one of them is a first degree relative of the other two;
FAP is excluded*
2. At least 2 of the above persons are first degree relatives from
two different generations
3. At least 1 of the above persons has cancer diagnosed at age
under 50 years
All other parameters (right side localization, syn- or metachronous 
tumours) should be treated as non-diagnostic features.
*Colorectal polyposis, congenital hypertrophy of the retinal pigment 
epithelium, cysts and osteomas of the mandible/maxilla and desmoids 
are excluded
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F Fi ig gu ur re e   1 1. .   Family pedigree matching HNPCC criteria, according to
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a highly increased risk of disease [12-15]. According to
our experience the criteria summarized in Table 2 are of
particular value in identifying cases suspected of HNPCC.
Examples of families matching the criteria of
“suspected HNPCC” are presented in Figures 2-3.
M Mo ol le ec cu ul la ar r   d di ia ag gn no os st ti ic cs s   o of f   c co on ns st ti it tu ut ti io on na al l
m mu ut ta at ti io on ns s   i in n   g ge en ne es s   a as ss so oc ci ia at te ed d   
w wi it th h   H HN NP PC CC C
Such diagnostics was described in the section
“MSH2/MLH1 testing”. Detection of marker mutation
for a family with HNPCC is of clinical importance
because it:
a) allows exclusion of around 50% of relatives from
the high risk group, and
b) facilitates surgical decision making, for example
instead of a classical tumour resection colectomy
with prophylactic hysterectomy and ovariectomy
when such resections are performed in female
mutation carriers at perimenopausal age.
M Ma an na ag ge em me en nt t   o of f   f fa am mi il li ie es s   w wi it th h   H HN NP PC CC C
Our present knowledge about this syndrome
indicates that special prevention and treatment should
be applied. Different programmes are performed by
particular centres [4, 16, 17]. According to the latest
data, relatives from families with Lynch syndrome
should consider the following options of medical
management.
D Di ie et t  o op pt ti im mi iz za at ti io on n
Persons with high risk of CRC should consider 
a low fat diet with limitations concerning red meat, but
with bran and rich in cellulose [18]. 
P Ph ha ar rm ma ac co ol lo og gi ic ca al l  p pr re ev ve en nt ti io on n  
There are reports that the group of drugs lowering
the risk of CRC includes: aspirin, sulindac, prioxicam,
calcium, and vitamin C. The real value of such drugs
in cancer prevention in HNPCC cannot be excluded,
but is not proven [17, 19, 20].
C Co ol lo on no os sc co op py y  
Full colonoscopy is recommended from the ages
of 20-25 years every one – two years. In families in
which CRC has been diagnosed at earlier ages
colonoscopy should begin 5 years earlier than the age
of the youngest person with CRC. In cases where
endoscopy the colon could not be assessed properly,
a barium enema is indicated [17, 21].
E Ex xt tr ra a- -c co ol lo on ni ic c  t tu um mo ou ur r  d di ia ag gn no os st ti ic cs s  
Due to the increased frequency of female genital
tract tumours in women with HNPCC, it is recommended
to perform, beginning at the age of 35 years, annual
clinical gynaecological examinations with transvaginal
ultrasonography (USG) and histopathological
examination of the endometrium. Additionally, in some
cases it is indicated to perform an examination aimed
at detecting other tumours more frequently observed in
a given family (for example stomach, urinary tract and
breast) [5, 17].
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T Ta ab bl le e   2 2. .   Diagnostic criteria of “suspected HNPCC” [16]
1. Among first degree relatives of a CRC patient (or in himself) 
at least one CRC, cancer of the endometrium, small bowel 
or urinary tract
2. At least one of the above cancers diagnosed under age 50
3. FAP is excluded*
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S Su ur rg ge er ry y  
Endoscopic polypectomy is recommended in the case
of polyps which are benign and non-recurrent. However,
in patients with adenomas that are multiple and/or
recurrent and/or of a significant degree of dysplasia
and/or villous, prophylactic colectomy should be
considered [21]. Most experts believe that prophylactic
surgery should not be recommended to patients without
any pathological changes of the colon even if such
persons are carriers of a mutation [17]. The high
proportion of synchronous tumours (more than 15% of
patients at the time of diagnosis) or metachronous
tumours (about 45% during 10 years following surgery
of the primary tumour) suggests that for preventive surgery
as for surgery in patients from HNPCC families with
histopathologically diagnosed CRC the following types
of surgical treatment can be recommended [17, 21]:
• proctocolectomy with ileostomy,
• colectomy with ileo-rectal anastomosis,
• proctocolectomy with ileo-anal “pouch” – S, J, W or H.
The first of the proposed procedures is the most
radical but later the risk of recurrence is very low.
However, such treatment is highly traumatising and
frequently leads to urinary tract abnormalities and
sexual dysfunction.
Colectomy with ileorectal anastomosis does not
lead to such complications but should be followed by
frequent examinations due to the risk of cancer in the
unresected fragment of bowel.
Proctocoloctomy with ileo-anal “pouch” S, J, W or
H is a method with a relatively short history so it is
difficult to conclude about it definitely.
In females with Lynch syndrome undergoing surgery
due to CRC and at perimenopausal age or older, due
to increased risk of primary endometrial and ovarian
cancers, it is recommended to consider extension of
the surgery by hysterectomy and adnexectomy [17, 22].
All of the above procedures are characterized by
increasing frequency of complications. However, they
are recommended in the treatment of HNPCC because
the really important problem for this patient is the high
risk of second primary CRC. 
It has been shown that the application of
appropriate programmes of management in families
with HNPCC leads to increased detection of early
asymptomatic CRC. Additionally, prospective studies
have confirmed that due to appropriate management
the lifetime risk of CRC decreases, from 80 to 30%,
and there is a higher proportion of healing and longer
survival time of patients with CRC from families with
Lynch syndrome. Correct management applied in
carriers of MSH2/MLH1 mutations means that such
persons cannot die due to CRC [23].
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